The use of NAIs for the treatment of influenza in adults confers a small decrease in time to symptom alleviation (17 hours). The statistical heterogeneity for the treatment analysis was reported to be low. The Cochrane review employed the use of clinical study reports from national drug regulators, in addition to studies published in biomedical journals. This resulted in a comprehensive study that better represents the effects of these medications. Although the meta-analysis only included RCT’s, limitations such as selective publication, inclusion of non-peer-reviewed data, and high attrition rates negatively impacted the quality of the evidence. A subgroup analysis on the treatment effect of zanamivir between influenza-positive and influenza-negative patients revealed that both populations had an identical duration of reduction in symptoms. A recent open-label RCT published in January 2020 (the ALIC4E trial) also showed that patients with symptomatic influenza treated with oseltamivir plus usual care recovered 1 day (95% CI 0.74 to 1.31) sooner than those who received usual care alone. As demonstrated in the Cochrane review, this reduction occurred equally in influenza positive and influenza negative groups, irrespective of laboratory confirmed influenza. This suggests that NAIs most likely do not have an influenza-specific effect in symptom alleviation, or as likely that this was a placebo effect given that the study was unblinded and patients knew if they were receiving an NAI. The use of NAIs in healthy children may reduce time to symptom alleviation by about a day, but carries the risk of adverse events.
The systematic review did not report outcomes where incidence was less than 0.5%, and this included mortality. Lack of clarity regarding mortality is unfortunate, given the estimated 200,000-600,000 estimated annual deaths worldwide due to influenza. It is important to note that the Infectious Diseases Society of America (IDSA) and the Centers for Disease Control and Prevention (CDC) endorse the consideration of NAIs for all people with influenza-like illness within 48 hours of onset. These groups recommend NAIs for all persons at higher risk of dying from influenza (i.e. immunocompromised status, advanced age, multiple comorbidities) and for all persons hospitalized with influenza. These recommendations are based on observational data and expert opinion. Unfortunately, we do not have strong data to support these recommendations, and given their widespread use, it is hard to imagine we will see a randomized control trial in the future, answering the questions “Do NAIs save lives?” or “Is there a benefit with NAIs in people who are very sick (hospitalized)?”
The data for NAIs are further confounded by the financial conflicts of interest that are present in many of the studies on NAI use. Dunn et al demonstrated that among NAI studies associated with a FCOI, 88% of the studies were classified as favorable. For those without FCOI (among which was this Cochrane review), 17% of the studies were classified as favorable. Thus, much of the positive data regarding NAI is heavily biased.
In summary, the existing data indicate that NAIs reduce the duration of symptoms by less than a day in patients with confirmed or suspected influenza. The use of NAIs to treat influenza does not prevent hospitalization and is associated with adverse events. Therefore, we have assigned a color recommendation of yellow (unclear if it provides benefit, more data needed) to this treatment.
The original manuscript was published in
Academic Emergency Medicine as part of the partnership between TheNNT.com and AEM.
See theNNT.com's previous reviews of this topic:
Neuraminidase Inhibitors Given for Influenza, January 26, 2010